Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $10.6 million.

  • Protagonist Therapeutics' Share-based Compensation rose 387.6% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 2653.59%. This contributed to the annual value of $37.6 million for FY2024, which is 2820.13% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Share-based Compensation of $10.6 million as of Q3 2025, which was up 387.6% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Share-based Compensation ranged from a high of $13.8 million in Q1 2025 and a low of $2.7 million during Q1 2021
  • Over the past 5 years, Protagonist Therapeutics' median Share-based Compensation value was $6.8 million (recorded in 2022), while the average stood at $7.5 million.
  • In the last 5 years, Protagonist Therapeutics' Share-based Compensation soared by 15541.43% in 2021 and then skyrocketed by 387.6% in 2025.
  • Protagonist Therapeutics' Share-based Compensation (Quarter) stood at $5.0 million in 2021, then increased by 9.71% to $5.5 million in 2022, then rose by 19.76% to $6.6 million in 2023, then soared by 37.75% to $9.1 million in 2024, then grew by 16.12% to $10.6 million in 2025.
  • Its Share-based Compensation was $10.6 million in Q3 2025, compared to $10.9 million in Q2 2025 and $13.8 million in Q1 2025.